| Title |
Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, April 2016
|
| DOI | 10.2147/dmso.s97036 |
| Pubmed ID | |
| Authors |
Linda Avallone, Ali Shaikh, Amir Hassan, Nadeem Tajuddin |
| Abstract |
Type 2 diabetes mellitus (T2DM) and metabolic syndrome contribute to hypertriglyceridemia, which may increase residual risk of cardiovascular disease in patients with elevated triglyceride (TG) levels despite optimal low-density lipoprotein cholesterol (LDL-C) levels with statin therapy. Prescription products containing the long-chain omega-3 fatty acids (OM3FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are an effective strategy for reducing TG levels. This article provides an overview of prescription OM3FAs, including relevant clinical data in patients with T2DM and/or metabolic syndrome. Prescription OM3FAs contain either combinations of DHA and EPA (omega-3-acid ethyl esters, omega-3-carboxylic acids, omega-3-acid ethyl esters A) or EPA alone (icosapent ethyl). These products are well tolerated and can be used safely with statins. Randomized controlled trials have demonstrated that all prescription OM3FAs produce statistically significant reductions in TG levels compared with placebo; however, differential effects on LDL-C levels have been reported. Products containing DHA may increase LDL-C levels, whereas the EPA-only product did not increase LDL-C levels compared with placebo. Because increases in LDL-C levels may be unwanted in patients with T2DM and/or dyslipidemia, the EPA-only product should not be replaced with products containing DHA. Available data on the effects of OM3FAs in patients with diabetes and/or metabolic syndrome support that these products can be used safely in patients with T2DM and have beneficial effects on atherogenic parameters; in particular, the EPA-only prescription product significantly reduced TG, non-high-density lipoprotein cholesterol, Apo B, remnant lipoprotein cholesterol, and high-sensitivity CRP levels without increasing LDL-C levels compared with placebo. Ongoing studies of the effects of prescription OM3FAs on cardiovascular outcomes will help determine whether these products will emerge as effective add-on options to statin therapy for reduction of residual cardiovascular disease risk. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 17% |
| Researcher | 7 | 13% |
| Student > Postgraduate | 6 | 11% |
| Professor > Associate Professor | 5 | 9% |
| Other | 4 | 8% |
| Other | 10 | 19% |
| Unknown | 12 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 34% |
| Nursing and Health Professions | 6 | 11% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Agricultural and Biological Sciences | 4 | 8% |
| Other | 2 | 4% |
| Unknown | 14 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2023.
All research outputs
#2,197,677
of 25,576,275 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#109
of 1,189 outputs
Outputs of similar age
#35,192
of 315,173 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#3
of 7 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,189 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,173 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.